verkazia Drug Patent Profile
✉ Email this page to a colleague
When do Verkazia patents expire, and when can generic versions of Verkazia launch?
Verkazia is a drug marketed by Harrow Eye and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and fifteen patent family members in twenty-three countries.
The generic ingredient in VERKAZIA is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Verkazia
A generic version of verkazia was approved as cyclosporine by HIKMA on October 29th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for verkazia?
- What are the global sales for verkazia?
- What is Average Wholesale Price for verkazia?
Summary for verkazia
| International Patents: | 115 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Patent Applications: | 4,376 |
| Drug Prices: | Drug price information for verkazia |
| What excipients (inactive ingredients) are in verkazia? | verkazia excipients list |
| DailyMed Link: | verkazia at DailyMed |
Pharmacology for verkazia
| Drug Class | Calcineurin Inhibitor Immunosuppressant |
| Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
US Patents and Regulatory Information for verkazia
verkazia is protected by seven US patents and two FDA Regulatory Exclusivities.
Patents protecting verkazia
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS IN CHILDREN AND ADULTS
Emulsion compositions containing quaternary ammonium compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion compositions containing quaternary ammonium compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions containing quaternary ammonium compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion compositions containing cetalkonium chloride
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion compositions containing quaternary ammonium compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting verkazia
FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS
Exclusivity Expiration: ⤷ Sign Up
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for verkazia
See the table below for patents covering verkazia around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | E479424 | ⤷ Sign Up | |
| Hungary | E030841 | ⤷ Sign Up | |
| Japan | 5122969 | ⤷ Sign Up | |
| Cyprus | 1114457 | ⤷ Sign Up | |
| Japan | 5587936 | ⤷ Sign Up | |
| Mexico | 2007003045 | EMULSIONES OFTALMICAS QUE CONTIENEN UN AGENTE INMUNOSUPRESOR. (OPHTHALMIC EMULSIONS CONTAINING AN IMMUNOSUPPRESSIVE AGENT.) | ⤷ Sign Up |
| South Korea | 20090047496 | COMPOSITIONS CONTAINING QUATERNARY AMMONIUM COMPOUNDS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for verkazia
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1809237 | 300741 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CICLOSPORINE (EYE DROP EMULSION); REGISTRATION NO/DATE: EU/1/15/990 20150323 |
| 1809237 | C01809237/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: CICLOSPORIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66093 08.09.2016 |
| 1809237 | CA 2015 00030 | Denmark | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORINOEJENDRABEEMULSION; REG. NO/DATE: EU/1/15/990/001-002 20150319 |
| 1809237 | C300741 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CICLOSPORINE (EYE DROP; REGISTRATION NO/DATE: EU/1/15/990 20150319 |
| 1809237 | CR 2015 00030 | Denmark | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORIN; REG. NO/DATE: EU/1/15/990/001-002 20150323 |
| 1809237 | 122015000043 | Germany | ⤷ Sign Up | PRODUCT NAME: OPHTHALMISCHE EMULSION ENTHALTEND CYCLOSPORIN; REGISTRATION NO/DATE: EU/1/15/990 20150319 |
| 2049079 | LUC00006 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
